TY - JOUR
T1 - Anaplastic thyroid carcinoma
T2 - Treatment in the age of molecular targeted therapy
AU - Cabanillas, Maria E.
AU - Zafereo, Mark
AU - Gunn, G. Brandon
AU - Ferrarotto, Renata
N1 - Publisher Copyright:
Copyright © 2016 by American Society of Clinical Oncology.
PY - 2016/6
Y1 - 2016/6
N2 - Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity bywhich it grows has been amajor barrier to progress in finding effective therapies. Thus, the treatment that is the current standard of care for these patients is largely palliative, andfeware cured;however,novel therapies andapproaches are being studied in patients with anaplastic thyroid carcinoma and are delineated herein.
AB - Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity bywhich it grows has been amajor barrier to progress in finding effective therapies. Thus, the treatment that is the current standard of care for these patients is largely palliative, andfeware cured;however,novel therapies andapproaches are being studied in patients with anaplastic thyroid carcinoma and are delineated herein.
UR - http://www.scopus.com/inward/record.url?scp=84974574975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84974574975&partnerID=8YFLogxK
U2 - 10.1200/JOP.2016.012013
DO - 10.1200/JOP.2016.012013
M3 - Review article
C2 - 27288464
AN - SCOPUS:84974574975
SN - 1554-7477
VL - 12
SP - 511
EP - 518
JO - Journal of oncology practice
JF - Journal of oncology practice
IS - 6
ER -